Start with the pathway
The Peptides Made Clear Three-Pathway Model
FDA-Approved Medication
An FDA-approved medication has undergone formal agency review for a specific formulation, manufacturer, labeling, quality standard, and intended use. Approval applies to that specific finished product—not automatically to every product containing the same active ingredient.
Expand context
FDA-Approved Medication
The approval record connects a defined finished product to reviewed manufacturing controls, prescribing information, and an approved use. A shared ingredient name does not transfer that approval to another formulation or source.
Compounded Medication
A compounded medication is prepared through a licensed healthcare and pharmacy pathway to meet a medical need. It may involve a provider evaluation, prescription, licensed pharmacy, patient-specific label, pharmacy records, and clinical follow-up. Compounded medications are not FDA-approved finished drugs.
Expand context
Compounded Medication
The applicable pathway and requirements depend on how and where the preparation is made. The pharmacy or outsourcing facility—not an FDA product approval—provides the relevant preparation and accountability framework.
Research-Use-Only Material
A research peptide is supplied for laboratory investigation. It is not dispensed as medication and does not include a medical evaluation, prescription, patient-specific directions, pharmacy record, or clinical monitoring.
Expand context
Research-Use-Only Material
Documentation may describe a sample, lot, or analytical result, but research labeling and supplier records do not create a patient-care pathway or establish suitability for human use.
Compare the systems
Same compound name, different framework
| Question | FDA-Approved Medication | Compounded Medication | Research Peptide |
|---|---|---|---|
| Intended for patient treatment? | Yes | Yes, when legally prescribed | No |
| FDA-approved finished product? | Yes | No | No |
| Prescription pathway? | Yes | Generally required for patient-specific 503A compounding | No |
| Dispensed through a pharmacy? | Yes | Yes | No |
| Patient-specific label? | Yes | Generally yes | No |
| Clinical support? | Typically available | May be included | Not included |
| Primary intended use? | Approved medical use | Patient care | Laboratory research |
Intended for patient treatment?
- FDA-approved
- Yes
- Compounded
- Yes, when legally prescribed
- Research
- No
FDA-approved finished product?
- FDA-approved
- Yes
- Compounded
- No
- Research
- No
Prescription pathway?
- FDA-approved
- Yes
- Compounded
- Generally required for patient-specific 503A compounding
- Research
- No
Dispensed through a pharmacy?
- FDA-approved
- Yes
- Compounded
- Yes
- Research
- No
Patient-specific label?
- FDA-approved
- Yes
- Compounded
- Generally yes
- Research
- No
Clinical support?
- FDA-approved
- Typically available
- Compounded
- May be included
- Research
- Not included
Primary intended use?
- FDA-approved
- Approved medical use
- Compounded
- Patient care
- Research
- Laboratory research
Read the report precisely
A COA Is Evidence—Not the Entire Answer
A reported purity percentage addresses one analytical question. Product documentation becomes more informative when each result is tied to the exact sample, lot, method, date, and laboratory.
Identity
Does the analytical result support that the sample is the expected compound?
Purity
How much of the detected material appears to be the principal compound rather than related impurities?
Quantity
Does the vial contain the amount stated on its label?
Sterility
Were viable microorganisms detected under the specified test conditions?
Bacterial Endotoxins
Were bacterial toxins detected above the laboratory’s reported limit?
Stability
Does the product remain within specifications over time under stated storage conditions?
These tests answer different questions. One passing result should never be presented as proof that every quality attribute was tested.
Our signature document check
The Peptides Made Clear “CLEAR” COA Check
Step 1 of 5
Confirm the compound
Does the report identify the exact compound and sample tested?
Compare like with like
Why Prices Differ
Compounded or Provider-Led Pricing May Include
- Provider evaluation
- Prescription processing
- Pharmacy preparation
- Patient-specific labeling
- Supplies
- Specialized shipping
- Clinical follow-up
- Administrative and regulatory costs
Research Pricing Generally Covers
- Research material
- Order fulfillment
- Available batch documentation
- Supplier support
- Any testing included by that supplier
A clinical-program price and a research-vial price are not direct comparisons. They represent different products, services, responsibilities, and intended uses.
Claims need context
Marketing Terms That Require Verification
These phrases may sound official, but they do not independently establish FDA approval, pharmacy dispensing, or a particular regulatory category.
Questions to Ask
- Is the finished product FDA approved?
- Is a prescription required?
- Which pharmacy dispenses it?
- Is the facility operating under 503A or registered under 503B?
- Which tests were performed on the current batch?
- Can the supporting documents be independently verified?
Two compounding pathways
503A vs. 503B
503A
Generally associated with patient-specific compounding by qualifying licensed pharmacists, pharmacies, federal facilities, or physicians. A valid prescription for an identified patient is central to this pathway.
503B
A separate category for registered outsourcing facilities. These facilities may prepare larger batches for healthcare settings and are subject to additional federal requirements.
Keep the categories separate
What Testing Cannot Change
- A COA does not create a prescription.
- A purity result does not establish sterility.
- Testing does not change a product’s intended use.
- An RUO label does not permit medical marketing.
- A pharmacy label does not make a compounded preparation FDA approved.
- A shared compound name does not make two finished products equivalent.
The practical rule
Final Takeaway
Before comparing price, begin with the pathway.
Ask what the product is intended for, who is accountable for it, what was actually tested, and what remains unknown.
That is the difference between seeing a product claim and understanding the evidence behind it.
Common questions
Frequently Asked Questions
Are compounded peptides FDA approved?
No. Compounded medications are not FDA-approved finished drugs. They may be prepared under a lawful compounding pathway, but FDA does not review each compounded preparation for safety, effectiveness, and quality before marketing.
Are compounded and research peptides interchangeable?
No. They may reference the same molecule, but they have different intended uses, records, labels, oversight, and accountability systems.
Does 99% purity mean a product passed every test?
No. Purity is one analytical result. It does not by itself establish identity, quantity, sterility, endotoxin status, stability, or suitability for any use.
Does “pharmacy grade” mean FDA approved?
No. The phrase does not independently establish FDA approval, pharmacy dispensing, or a defined regulatory category. Verify the finished product and its actual pathway.
Does a COA make a research peptide appropriate for human use?
No. A certificate reports the tests and results shown on that document. It does not create a prescription, clinical supervision, or approval for human use.
What is the difference between 503A and 503B?
Section 503A generally centers on patient-specific compounding by qualifying licensed practitioners or pharmacies. Section 503B establishes registered outsourcing facilities that may compound larger batches for healthcare settings under additional federal requirements. Neither pathway makes each compounded product FDA approved.
Official references
Primary Sources
Continue learning